

Our Mission

. . . . is to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation.



Our Vision

. . . . is to integrate with USAMRMC, Federal agencies, and the DoD, as part of the joint biomedical research and materiel community, to focus on delivering the best medical solutions for today and tomorrow.

Our products are an integral part of the DoD Force Health Protection Program, to include vaccines, drugs, and medical devices, to prevent, diagnose, and treat infectious diseases, combat-related casualties, and CBRNE threats.

Our products enhance from recruit training to far-forward medical care across the full spectrum of health care missions worldwide.



USAMMDA
1430 Veterans Drive
Fort Detrick, MD 21702
301.619.7056
www.usammda.army.mil

USAMRMC



**U.S. Army
Medical Research
Materiel Command**

Adenovirus Vaccine



USAMMDA

**U.S. Army Medical Materiel
Development Activity**

*Developing Quality Medical Products
for U.S. Forces*


Protect the Warrior; Sustain the Force.

Updated: October 2009

Adenovirus Vaccine . . .

The Adenovirus Vaccine has been used by the Department of Defense to prevent adenovirus-related acute respiratory disease in military recruits during basic training, while living in barracks-type environments. Since the adenovirus can spread via direct contact, airborne transmission and droplet transmission, the close quarters of recruit life make them highly susceptible to exposure.

Adenovirus infections in military recruits are associated with pharyngitis, conjunctivitis, rhinitis and pneumonia. These illnesses often lead to missed training and some recruits have to repeat parts of the training cycle.



Distribution . . .

The Adenovirus Vaccine is two orally administered, enteric-coated tablet containing live adenovirus serotypes 4 or 7.

Each initial-entry recruit will receive a one-time dose of both serotypes, along with their other immunizations, during in-processing.

Vaccine Development . . .

A contract to develop and manufacture the types 4 and 7 adenovirus vaccine was awarded to Barr Pharmaceuticals in 2001. In July 2004, Barr submitted the Investigational New Drug (IND) application to the FDA. Clinical studies were carried out jointly by the Army and Navy. The Phase 1 clinical trial was completed in April 2005 at Fort Sam Houston, TX. A successful Phase 3 clinical trial began in September 2006 at Ft. Jackson, SC and Naval Training Center, Great Lakes, IL. A Biological License Application is to be submitted to the FDA in 2008. The licensed vaccine is expected to be available in 2009.




DOD and Barr production staff at the Barr facility in Forrest, VA in March 2007.



Representatives from USAMMDA observe the processes and equipment for manufacturing the Adenovirus Vaccine tablets at the new facility in Forrest, VA.

History and Timeline . . .



For additional information, contact:

COL Arthur Brown, Product Manager
301.619.0232
arthur.brown@amedd.army.mil